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Abstract: Nephrotoxicity is a relevant limitation of gentamicin, and obese patients have an increased
risk for gentamicin-induced kidney injury. This damage is thought to depend on the accumulation of the
drug in the renal cortex. Obese rats showed substantially higher levels of gentamicin in the kidney than
did lean animals. This study characterized the role of organic cation transporters (OCTs) in gentamicin
transport and elucidated their possible contribution in the increased renal accumulation of gentamicin in
obesity. The mRNA and protein expression levels of the organic cation transporters Oct2 (Slc22a2) and
Oct3 (Slc22a3) were increased in kidney samples from obese mice fed a high-fat diet. Similarly, OCT2 (￿2-
fold) and OCT3 (￿3-fold) showed increased protein expression in the kidneys of obese patients compared
with those of nonobese individuals. Using HEK293 cells overexpressing the different OCTs, human OCT2
was found to transport [(3)H]gentamicin with unique sigmoidal kinetics typical of homotropic positive
cooperativity (autoactivation). In mouse primary proximal tubular cells, [(3)H]gentamicin uptake was
reduced by approximately 40% when the cells were coincubated with the OCT2 substrate metformin.
The basolateral localization of OCT2 suggests that gentamicin can enter proximal tubular cells from the
blood side, probably as part of a slow tubular secretion process that may influence intracellular drug
concentrations and exposure time. Increased expression of OCT2 may explain the higher accumulation
of gentamicin, thereby conferring an increased risk of renal toxicity in obese patients.
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Nephrotoxicity is a relevant limitation of gentamicin and obese patients have an increased risk 23 
for gentamicin-induced kidney injury. Drug-induced kidney injury is thought to depend on the 24 
accumulation of the drug in the cortex. Obese rats showed substantially higher levels of 25 
gentamicin in the kidney compared with lean animals. This study characterized the role of 26 
organic cation transporters (OCTs) in gentamicin transport and elucidated their contribution in 27 
the increased renal accumulation of gentamicin in obesity. The mRNA and protein expression 28 
levels of the organic cation transporters Oct2 (Slc22a2) and Oct3 (Slc22a3) were increased in 29 
kidney samples from obese mice fed a high-fat diet. Similarly OCT2 (~2-fold) and OCT3 30 
(~3-fold) showed increased protein expression in the kidney of obese patients compared with 31 
non-obese individuals. Using HEK293 cells overexpressing the different OCTs, human OCT2 32 
was found to transport [3H]gentamicin with unique sigmoidal kinetics typical of homotropic 33 
positive cooperativity (autoactivation). In mouse primary proximal tubule cells, [3H]gentamicin 34 
uptake was reduced by 40%, when co-incubated with the OCT2 substrate metformin. The 35 
basolateral localization of OCT2 suggests that gentamicin can enter proximal tubular cells 36 
from the blood side, probably as part of a slow tubular secretion process that may influence 37 
intracellular drug concentrations and exposure time. Increased expression of OCT2 may 38 
explain the higher accumulation of gentamicin, thereby conferring an increased risk of renal 39 
toxicity in obese patients.  40 
 41 




Gentamicin and aminoglycosides in general are very effective in treating a variety of 44 
Gram-negative bacterial infections but their use has been limited by nephrotoxicity and 45 
ototoxicity (1, 2). However, the development of multidrug resistant infections has led this class 46 
of antibiotics to be reconsidered in a number of clinical situations (3). Aminoglycosides have a 47 
higher incidence of nephrotoxicity in obesity (4). As obesity has become more prevalent, with 48 
currently more than 36% of the US population obese, the overall risk of 49 
aminoglycoside-induced nephrotoxicity may increase (5, 6). A better understanding of the 50 
underlying mechanisms of aminoglycoside-induced nephrotoxicity could help to design 51 
efficient protective strategies. 52 
Animal studies have demonstrated that obese and lean rats had similar plasma gentamicin 53 
concentrations, yet accumulation of the drug in the kidney was greater in the obese group (7). 54 
The kidneys are key organs in the elimination of drugs. The processes involved in renal 55 
excretion include glomerular filtration, tubular reabsorption and tubular secretion and are 56 
governed by several protein-mediated transport systems (8). The disruption of tubular 57 
reabsorption or secretion due to altered expression and/or activity of these carriers can alter 58 
the disposition of many drugs (9, 10). Obesity is associated with several pathophysiological 59 
changes (11, 12). As regards renal function, obesity has been reported as an independent risk 60 
factor for chronic kidney disease, leading to glomerulosclerosis and renal insufficiency (13-16). 61 
Nonetheless, the effects of obesity on the expression of transporters involved in tubular 62 
reabsorption and secretion are poorly explored. 63 
We previously analyzed the gene expression pattern of a variety of renal transporters in obese 64 
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mice (16). The expression of several solute carrier 22 (SLC22) family members was altered in 65 
the kidney of high-fat diet (HFD) induced obese mice compared with that of lean mice. The 66 
SLC22 family comprises organic cation transporters (OCTs), organic carnitine/cation 67 
transporters (OCTNs), and organic anion transporters (OATs) (17). Aminoglycosides are 68 
polycations and are likely to require protein-mediated transport to cross the cell membrane. 69 
Studies in knockout mice showed that megalin-mediated endocytosis from the apical side is 70 
the main mechanism for gentamicin uptake in the proximal tubule, whereas in rats the 71 
endocytic uptake played only a marginal role in gentamicin renal transport (18-21), suggesting 72 
that multiple transport systems can be involved in gentamicin renal accumulation with varying 73 
individual contributions. 74 
Our data indicate that the expression of OCTs at the basolateral side of proximal tubular cells 75 
is increased in obesity and that OCT2 (SLC22A2) mediates the uptake and retention of 76 
[3H]gentamicin in our in vitro model. The data show that organic cation transporters could 77 
contribute to the transport of gentamicin and explain the higher incidence of 78 
gentamicin-induced nephrotoxicity in obesity (22).  79 
 80 
Materials and Methods 81 
Reagents 82 
Gentamicin [3H(G)] sulfate ([3H]gentamicin) was purchased from American Radiolabeled 83 
Chemicals (St. Louis, MO), 4-(4-(dimethylamino)-styryl)-N-methylpyridinium iodide (ASP+)) by 84 
Molecular Probes-Life Technologies (Carlsbad, Ca). Non-labeled gentamicin sulfate and 85 
non-labeled metformin were provided by Sigma-Aldrich (St.Louis, MO). All cell culture 86 
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reagents were purchased from Gibco (Parsley, UK). 87 
 88 
Animal procedures  89 
Female C57/BJ mice aged 6 weeks were randomly assigned to a high-fat diet (HFD; D12331; 90 
Provimi Kliba, Switzerland) or a chow diet (D12329; Provimi Kliba, Switzerland). All mice were 91 
sacrificed under anesthesia 16 weeks after treatment and their kidneys were harvested. Half of 92 
the kidney from each animal was snap frozen in liquid nitrogen and stored at –80°C for RNA 93 
and protein extraction. The other half was fixed with formalin for histological examination. 94 
 95 
Measurement of plasma samples 96 
Plasma samples were obtained from the tail blood of fasted mice. Plasma cholesterol and 97 
triglyceride (TG) levels were measured by the Amplex Red cholesterol assay kit (A12216, 98 
Thermo Fisher Scientific, Carlsbad, CA) and the triglyceride assay kit (ETGA-200, EnzyChrom, 99 
Aachen, Germany), respectively. 100 
 101 
Patients 102 
Twenty-eight patients of Asian ethnicity with Minimal Change Disease (MCD) of the kidney, as 103 
diagnosed by ultrasonography-guided percutaneous biopsy, were included. The exclusion 104 
criteria were: (a) Body Mass Index (BMI) > 40kg/m2; (b) history of type 2 diabetes mellitus; (c) 105 
renal, cardiovascular (heart failure, previous myocardial infarction), liver or thyroid diseases; (d) 106 
use of drugs known to affect the parameters under investigation. Participants had stable body 107 
weight (weight change < 5 kg during the last 6 months). Demographic data on both groups, 108 
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such as gender, age, weight, and plasma lipids are shown in Table 3. BMI was calculated 109 
according to the WHO. Appropriate BMI for Asian Populations and the Criteria of Weight and 110 
BMI for Chinese Adults, in which BMI<24 is normal and BMI>= 28 is defined as obese. 111 
 112 
Immunostaining  113 
Kidney sections were cut at 3 μm and immunostaining was performed on paraffin sections 114 
using a microwave-based antigen-retrieval technique. The antibodies used in this study 115 
included OCT2-SLC22A2 (Clone # 640438, R&D SYSTEMS, MN), OCT3-SLC22A3 116 
(ab124826, abcam, Cambridge, UK). Sections were treated with the Envision+ DAB kit (Dako, 117 
Denmark) according to the manufacturer’s instruction. Six mice were analyzed per group. The 118 
intensity of immunostainings for OCT2 and OCT3 on human biopsies was assessed 119 
according to protocols previously described (23). Briefly, digital images of random 120 
high-power fields were analyzed by an unbiased observer. The cross-sectional areas with 121 
positive staining were determined using Adobe Photoshop (version C3 for Windows). Six 122 
high-power fields were analyzed per biopsy. 123 
 124 
Western blotting  125 
Lysates (20 μg protein) from kidney tissue were separated by SDS-PAGE and blotted on 126 
polyvinylidene difluoride membranes (Millipore, Darmstadt, Germany). The membranes were 127 
blocked with TBS containing 0.1% Tween 20 and 3% BSA for 1 hour at room temperature and 128 
incubated overnight at 4°C with the respective antibodies. Subsequently, the blots were 129 
washed with TBS containing 0.1% Tween 20, treated with horseradish peroxidase conjugated 130 
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secondary antibodies at room temperature for 1 hour, and developed using the ECL Plus 131 
detection system (Amersham Biosciences, Little Chalfont, UK). The antibodies used in this 132 
study included OCT2-SLC22A2 (Clone # 640438, R&D SYSTEMS, MN), OCT3-SLC22A3 133 
(ab124826, abcam, Cambridge, UK). 134 
 135 
Isolation of primary proximal tubular cells  136 
Primary proximal tubular cells were isolated from kidneys of female C57/BJ mice as described 137 
previously (23). Briefly, kidney cortices were dissected, sliced, minced, and digested in 0.25% 138 
trypsin solution (Life Technologies BRL, Grand Island, NY) in a shaking incubator at 37°C for 1 139 
hour. Trypsin was neutralized with growth medium (DMEM and 10% FBS containing 100 U/ml 140 
penicillin and 0.1 mg/ml streptomycin). The suspension was pipetted and was passed through 141 
a 100 μm cell strainer (Becton Dickinson Labware, Franklin Lakes, NJ). The samples were 142 
centrifuged (72.4 x g for 5 minutes) to pellet the tubules, washed with 10 ml of medium, 143 
centrifuged, and washed twice more. The final pellet, consisting mostly of renal tubules, was 144 
resuspended in culture medium (REBM bullet kit, Clonetics, Basel, Switzerland), plated onto 145 
culture dishes and incubated at 37°C in a humidified atmosphere of 5% CO2 with medium 146 
changes every 2 days until the cells were confluent.  147 
 148 
Isolation of kidney and cell RNA and quantification of transcript levels  149 
Total RNA was isolated using the Trizol procedure (Thermo Fisher Scientific, Carlsbad, CA) 150 
and quantified at 260 nm. Two μg total RNA was reverse transcribed using oligo-dT priming 151 
and Superscript II (Thermo Fisher Scientific, Carlsbad, CA). First-strand complementary DNA 152 
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was used as the template for real-time polymerase chain reaction analysis with the Taqman® 153 
assay (Thermo Fisher Scientific, Carlsbad, CA). Transcript levels, determined in two 154 
independent complementary DNA preparations, were calculated and expressed relative to 155 
villin or β-actin as housekeeping genes.  156 
 157 
Cell lines  158 
Wild-type HEK293 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 159 
supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 0.1 mg/ml streptomycin at 160 
37°C in a humidified atmosphere of 5% CO2. HEK293 cells stably transfected with the human 161 
OCT1, OCT2 or OCT3, kindly provided by Dr. Hermann Koepsell, Würzburg, were 162 
supplemented with Geneticin G-418 (600 µg/ml) (24). 163 
 164 
Transport Studies in Intact Cells  165 
Uptake of the radiolabeled or fluorescent compounds was measured using a protocol 166 
designed for the quantification of uptake in cells (25). Cells were seeded in 35-mm dishes 167 
coated with 0.1 mg/ml poly-D-lysine (Sigma-Aldrich, St. Louis, MO). To perform the transport 168 
assay, the medium was aspirated and cells rinsed twice with pre-warmed transport buffer (136 169 
mM NaCl, 5.3 mM KCl, 1.1 mM KH2PO4, 1.8 mM CaCl2, 0.8 mM MgSO4, 11 mM D-glucose 170 
and 10 mM Hepes/Tris, pH 7.4). Cells were equilibrated in transport buffer at 37°C, the buffer 171 
was aspirated and transport buffer containing the radiolabeled or the fluorescent compound 172 
was added. Uptake was stopped by quick aspiration of the incubation cocktail followed by 173 
extensive washing with ice-cold transport buffer. Cells were digested for 45 min with 1 ml of 1% 174 
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(v/v) Triton X-100; 500 µl of the lysate was mixed with 4 ml of Scintillation Liquid (Ultima Gold, 175 
PerkinElmer, Switzerland) and assessed for intracellular radioactivity. Protein content was 176 
determined by the bicinchoninic acid protein assay on a 25 µl aliquot. 177 
To measure intracellular ASP+, the fluorescence (λex = 485nm, λem = 590nm) of a 150 µl aliquot 178 
was measured on the Twinkle LB970 microplate fluorometer (Berthold Technologies, 179 
Germany). Protein content was determined by the bicinchoninic acid protein assay on a 25 µl 180 
aliquot. OCT independent uptake was determined in WT-HEK293 cells, and subtracted from 181 
total uptake to quantify OCT mediated uptake.  182 
 183 
Statistical Analysis 184 
Comparisons for the transport assays were performed with the two-tailed Student's paired 185 
t-test. Statistics for mRNA and immunostaining expression assays, mouse and human patients’ 186 
parameters were based on the two-tailed Student’s unpaired t-test. All analyses were 187 
performed using GraphPad Prism (version 5.0 for Windows, GraphPad Software). 188 
 189 
Study approval  190 
Animal experiments and protocols conformed to the Guide for the Care and Use of 191 
Laboratory Animals (U.S. National Institutes of Health) and the Swiss animal protection 192 
laws and were approved by the Cantonal Veterinary Office in Zurich, Switzerland (study 193 
number 2012058). The human study was conducted according to the Declaration of 194 
Helsinki guidelines regarding ethical principles for medical research involving human 195 
subjects. All patients provided written informed consent, and the study protocol was 196 
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approved by the Scientific Ethical Committee of Shandong University, Jinan, China, where 197 
patients were based (license number SDU2015033). 198 
 199 
Results 200 
Body weight and plasma lipid levels in chow fed and obese mice 201 
Table 1 shows body weight and plasma lipid levels in chow and HFD fed mice. The body 202 
weight of obese mice was 30% higher than that of chow fed mice. The mean blood cholesterol 203 
and triglyceride levels in obese mice were significantly higher than those measured in chow 204 
mice, indicating that 16 weeks of HFD treatment induced obesity and hyperlipidemia. 205 
 206 
Effect of diet-induced obesity on organic cation transporter expression in the kidney 207 
Following on from previous microarray analyses of kidney RNA samples from chow and HFD 208 
fed mice (16), expression of a group of membrane carriers, compatible with aminoglycoside 209 
transport, was changed in obese mice (Table 2). Expression levels of Oct1, 2, 3, Octn1 and of 210 
the multidrug and toxin extrusion protein 1 and 2 (Mate1 and Mate2) were validated by mRNA 211 
quantification. HFD increased the expression of Oct2 and Oct3 at both the mRNA and protein 212 
levels (Figure 1 A and B), which was in line with the microarray results. Because it was 213 
reported to play a major role in gentamicin renal accumulation in mice, mRNA level of megalin 214 
was assessed. It can be seen that megalin expression level in HFD and chow mice was 215 
comparable, suggesting that megalin cannot account for the higher accumulation of 216 
gentamicin in obese. Immunostaining for Oct3 showed that this transporter is localized at the 217 
basolateral membrane of renal proximal tubules. The intensity of Oct3 staining was higher in 218 
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the obese mouse kidney than in the lean control group (Figure 1 C). 219 
 220 
Human OCT2 and OCT3 show increased expression in kidney biopsies of obese patients 221 
To investigate whether the enhanced expression of Oct2 and Oct3 in the kidney of obese mice 222 
is also evident in obese human subjects, immunostaining for OCT2 and OCT3 was performed 223 
in renal biopsy specimens from non-obese and obese human subjects who exhibited overt 224 
proteinuria >1g/day and had a diagnosis of minimal change disease. Patient characteristics 225 
are shown in Table 3. In line with the mouse data, OCT2 and OCT3 staining was more intense 226 
in the proximal tubules of obese patients compared to non-obese individuals (representative 227 
examples are shown in Figure 2 A-D) and quantification confirmed the increased expression of 228 
OCT2 (~2-fold) and OCT3 (~3-fold) in obese patients (Figure 2 C and F, respectively).  229 
 230 
OCT2 transports [3H]gentamicin 231 
To understand the role of organic cation transporters (OCTs) in gentamicin uptake, HEK293 232 
cells transfected with OCT1, OCT2 or OCT3 were co-incubated for 2 min (linear range) with 1 233 
µM of ASP+ (known OCT substrate) in the presence or absence of non-labeled gentamicin at 234 
an extracellular concentration of 10 mM (25, 26). Figure 3 A shows that non-labeled 235 
gentamicin reduced OCT2 mediated influx of ASP+ by approximately 50% (89.6 ± 17.5 vs 42.8 236 
± 10.6 pmol/mg of protein, P=0.02). OCT1- and OCT3-mediated transport was not affected by 237 
gentamicin. Figure 3 B shows the OCT2-mediated ASP+ influx at three different concentrations 238 
of substrate as a function of extracellular non-labeled gentamicin at the indicated 239 
concentrations (Dixon analysis). It can be seen that the lines intersect on the x-axis (-Ki), 240 
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indicating that the nature of the inhibition was non-competitive (Ki = 38.2 ± 4.4 mM) and 241 
suggesting that gentamicin and ASP+ did not bind to a common binding site. Transport of 242 
[3H]gentamicin mediated by OCT2 was measured at an extracellular concentration of 10 µM 243 
(Fig. 4 C). After a 30 minute incubation, the intracellular level of [3H]gentamicin in 244 
OCT2-HEK293 cells was markedly higher than in wild-type cells (25.9 ± 1.1 vs 16.0 ± 1.1 245 
pmol/mg of protein, P=0.002), indicating that OCT2 transported [3H]gentamicin at 246 
pharmacological concentrations. 247 
 248 
Kinetics of [3H]gentamicin influx mediated by OCT2. 249 
Influx of [3H]gentamicin as a function of concentration mediated by OCT2 was assessed over 4 250 
min and indicated saturability. However, non-hyperbolic kinetics rather than Michaelis-Menten 251 
kinetics were observed. The line was best-fit to a sigmoidal substrate-velocity curve indicating 252 
allosteric kinetics (Fig. 5 A and B). The non-linearity of the transformed equations 253 
(Hanes-Woolf and Eadie-Hofstee plots) further confirmed the allosteric interaction of 254 
gentamicin with OCT2 (Fig. 5 C and D). The concave upward curvature of the Hanes-Woolf 255 
plot of the data (Fig. 5 B) and a Hill coefficient computed to be 1.6±0.2 was consistent with a 256 
homotropic positive cooperativity (Fig. 5 B).  257 
 258 
Role of OCT2 in [3H]gentamicin uptake in primary proximal tubular cells (PTCs). 259 
To better understand the contribution of the endogenously expressed OCT2 on gentamicin 260 
transport, primary proximal tubular cells (PTCs) were isolated from kidneys of C57/BJ mice. 261 
The purity of the PTC preparation was assessed by measuring the mRNA expression levels of 262 
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villin, Oct2, and Mate1 in PTCs and glomerular fractions (not shown). Metformin, a known 263 
OCT2 substrate (27, 28) was used to inhibit the OCT2-mediated transport of [3H]gentamicin. In 264 
figure 6 A it can be seen that metformin in excess (10 mM) could abolish completely the 265 
OCT2-mediated transport of [3H]gentamicin in OCT2-HEK293 cells. Therefore, to assess the 266 
contribution of endogenous OCT2 in the uptake of [3H]gentamicin, the uptake of 267 
[3H]gentamicin at an extracellular concentration of 10 µM was measured in presence or 268 
absence of 10 mM metformin. In figure 6 B it can be seen that in presence of metformin the 269 
uptake of [3H]gentamicin was reduced by ~ 40% (P=0.04) suggesting a substantial 270 
contribution of OCT2 in the uptake of [3H]gentamicin in proximal tubular cells. 271 
 272 
Discussion 273 
Obese people have an increased susceptibility to aminoglycoside-induced nephrotoxicity but 274 
the mechanisms underlying this higher risk are unknown. Animal studies have demonstrated 275 
that obese and lean rats had similar plasma gentamicin concentrations, yet accumulation of 276 
the drug in the kidney was ~ 30% greater in the obese group suggesting that renal gentamicin 277 
uptake could be increased in the obese (7). Megalin-mediated endocytosis from the apical 278 
side has been demonstrated to be the main gentamicin uptake system in proximal tubules of 279 
knock-out mice (18, 21). The mechanism proposed involves an initial weak binding to acidic 280 
phospholipids on the brush-border membrane of the proximal tubule followed by accumulation 281 
of megalin in lysosomes and in the endoplasmic reticulum (21, 29-33).  282 
The mRNA expression level of megalin did not change in the kidney of our mouse model, 283 
conversely the expression of the main organic cation transporters OCT2 and OCT3 was 284 
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markedly increased in the kidney of HFD-induced obese mice and in kidney biopsies from 285 
obese patients. Hence, in consideration of the cationic nature of gentamicin, we hypothesized 286 
that OCTs could contribute to gentamicin renal uptake and that their increased expression 287 
might explain the augmented levels of gentamicin in the kidney of obese individuals, 288 
underscoring the role of OCTs in gentamicin uptake in proximal tubular cells (7, 34). It has 289 
been shown that megalin is not required for gentamicin accumulation in the HK-2 human renal 290 
proximal cell line and that co-incubation of gentamicin and mepiperphenidol, a prototype 291 
organic cation transporter inhibitor, could prevent gentamicin-induced toxicity in LLC-PK1 cells 292 
(35, 36). Along with this, in rats, megalin plays only a marginal role in gentamicin uptake, and 293 
yet, rats seem to be more sensitive than mice to gentamicin-induced kidney damage (18, 21), 294 
suggesting that other transport systems, besides megalin, contribute to the accumulation of 295 
gentamicin in the renal cortex and, subsequently, to the kidney damage.  296 
Among the different organic cation transporters expressed in the kidney, OCT2 was found to 297 
mediate the transport of [3H]gentamicin. Because OCT2 is expressed exclusively at the 298 
basolateral membrane, it appears to be an uptake system for gentamicin into proximal tubular 299 
cells from the blood circulation (17). In previous studies in dogs and rats, when the renal 300 
tubular handling of gentamicin was measured, no tubular secretion could be observed (37, 38). 301 
However, the same authors did not exclude a slow tubular secretory flux due to temporary 302 
sequestration of drug in the proximal tubular epithelium after uptake across the basolateral 303 
membrane (37). Whether gentamicin is (i) sequestered or (ii) free but not able to exit from the 304 
luminal side (e.g. poor substrate for the multidrug extrusion transporter, MATE1) is not clear. In 305 
either case, our study shows that gentamicin is actively transported by OCT2 as underscored 306 
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by the nephrotropism and ototropism of aminoglycosides, the main sites of expression of 307 
OCT2 in the human body (1, 2, 39, 40).  308 
Male gender, among others, was found to be a significant independent risk factor for 309 
aminoglycoside-associated nephrotoxicity in a study on 1489 patients prospectively monitored 310 
with individualized pharmacokinetic monitoring (41). Similarly, male rats were more prone than 311 
females to gentamicin-induced nephrotoxicity (42, 43). OCT2 expression is induced by 312 
testosterone, thus in general more abundant in males than in females (44). Notably, castration 313 
attenuated the gentamicin induced renal damage in male rats (45). The major role of OCT2 in 314 
tubular secretion is further demonstrated by the observation that bile duct ligation in rats 315 
induced the renal protein level of Oct2 and increased net tubular secretion even without any 316 
significant changes in the glomerular filtration (46).  317 
Kinetic data for the OCT2-mediated transport of gentamicin were well modeled empirically by 318 
the allosteric sigmoidal equation demonstrating positive homotropic cooperativity (Hill 319 
coefficient > 1) with increased binding affinity upon binding of a second gentamicin molecule. 320 
The structural complexity of the OCT binding pocket is known and for several substrates 321 
including choline, tetraethylammonium (TEA), and 1-methyl-4-phenylpyridinium (MPP), two 322 
binding sites have been described, but no cooperativity was reported (47-49). 323 
Substrate-dependent inhibitory ligand interaction is a common characteristic for OCT2 (49). 324 
The search for inhibitors that can disrupt such allosteric binding may potentially reduce the 325 
accumulation of gentamicin in the cortex avoiding nephrotoxicity in the clinical setting. 326 
Recently, metformin, a well-known OCT2 substrate, was demonstrated to prevent 327 
gentamicin-induced nephropathy in rats. Because at that time a role of OCT2 in gentamicin 328 
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transport was not considered, the effect of metformin on the renal accumulation of gentamicin 329 
was not explored (27, 28, 50). However, in light of the current findings it is possible that 330 
metformin could, to some extent, reduce the accumulation of gentamicin in the kidney, and 331 
buffer the renal damage.  332 
The exact mechanisms underlying the altered pharmacokinetics and toxicokinetics of 333 
gentamicin in obese patients have not been characterized. Here, we provide evidence that 334 
OCT2 could be an important delivery route for gentamicin from blood into the kidney. The role 335 
of OCT2 in gentamicin-induced nephrotoxicity proposed in this work, and underscored by the 336 
different clinical safety profile of gentamicin in defined cohorts of patients (e.g. male vs female, 337 
obese vs non-obese), should promote careful experimental design and kinetic interpretation of 338 
future inhibition studies aimed at defining suitable compounds that can specifically disrupt the 339 
gentamicin-OCT2 complex and thus protect patients from renal damage (4, 41, 42).  340 
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Figure Legends 354 
 355 
Figure 1. Effect of diet-induced obesity on organic cation transporter expression in 356 
kidney. (A) Quantification of mRNA levels of genes associated with cationic drug transport in 357 
mouse kidney. n=6 mice / group. Data are expressed as mean ± S.E.M., student’s t test, 358 
*p<0.05. (B) Western blot analysis of Oct2 and Oct3 protein levels in kidney samples of chow 359 
and HFD fed mice. (C) Representative images of immunostaining for Oct3 on kidney paraffin 360 
sections from the two groups. 361 
 362 
Figure 2. OCT2 and OCT3 expression in renal biopsy specimens from non-obese and 363 
obese human subjects with minimal change kidney disease. Representative images of 364 
immunostaining for OCT2 (A and B) and OCT3 (D and E) in kidney specimens obtained from 365 
non-obese (body mass index < 21 kg/m2, A, and D) and obese (body mass index > 25 kg/m2, 366 
B and E) patients with overt proteinuria (>1.0 g/d). Quantitative analysis of the positive staining 367 
of OCT2 (C) and OCT3 (F) per high-power field. Data are expressed as mean ± S.E.M., 368 
student’s t test, *p<0.05. 369 
 370 
Figure 3. Inhibition of the ASP+ OCT-mediated influx by non-labeled gentamicin. (A) 371 
Influx of 1 µM ASP+ was assessed in OCT1, OCT2 and OCT3 stably transfected HEK293 cells 372 
at pH 7.4 over 2 minutes in the absence (control) or presence of non-labeled gentamicin at an 373 
extracellular concentration of 10 mM. Uptake in WT-HEK293 cells was subtracted from that in 374 
transfected cells to define the OCT-specific transport. Data are expressed as percentage of the 375 
control. (B) ASP+ influx at the indicated extracellular concentrations (1, 5 or 20 µM) as a 376 
function of increasing extracellular concentrations of non-labeled gentamicin. The line is 377 
derived by plotting 1/v against the concentration of gentamicin (inhibitor) (Dixon analysis). 378 
Data represent the mean ± S.E.M. from three independent experiments.  379 
 380 
Figure 4. Time course of the net uptake of [3H]gentamicin in OCT-transfected cells. 381 
Uptake of [3H]gentamicin at an extracellular concentration of 10 µM in OCT1- (A), OCT2- (B), 382 
OCT3-HEK293 cells (C) was measured as a function of time and compared with that in 383 
wild-type cells. Data represent the mean ± S.E.M. from three independent experiments. 384 
 385 
Figure 5. Kinetic analysis of [3H]gentamicin influx. Initial uptake of [3H]gentamicin was 386 
assessed over 4 min at pH 7.4 in OCT2-transfected HEK293 cells. Data were corrected for 387 
uptake in wild-type cells. [3H]gentamicin influx as a function of substrate concentration. The 388 
data best-fit to the sigmoidal allosteric plot derived from the equation Y=Vmax*Xh/(Kprime + Xh) 389 
(A). Enlargement of the first part of the kinetic analysis (B). A Hanes-Woolf (C) and a 390 





Figure 6. Inhibitory effect of metformin on OCT2-mediated transport. Uptake of 394 
[3H]gentamicin at an extracellular concentration of 10 µM in OCT2-HEK293 cells was 395 
measured as a function of time in the presence or absence of non–labeled metformin. The 396 
results were corrected for uptake in wild-type cells and a representative experiment is shown 397 
(A). Uptake over 5 minutes of [3H]gentamicin at an extracellular concentration of 10 µM in the 398 
presence or absence of 10 mM non–labeled metformin was measured in primary proximal 399 
tubular cells (PTCs) isolated from kidneys of C57/BJ mice. Data are expressed as the 400 
percentage of [3H]gentamicin transport in the absence of non-labeled metformin and represent 401 
the mean ± S.E.M. from four independent experiments. *p<0.05 (B). 402 
 403 
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Table 1. Characteristics of mice in the chow and HFD groups after treatment 405 
 406 
groups Chow (n=6) HFD (n=6) 
Plasma Cho (mg/dl) 68.43 ± 1.918 85.58 ± 2.343* 
Plasma TG (mg/dl) 51.03 ± 3.703 62.23 ± 3.883* 
Body weight (g) 19.50 ± 0.500 25.50 ± 1.225* 
 407 
Abbreviations: HFD, high fat diet; TG, triglyceride; Cho, cholesterol. n=6 mice/group, data 408 






Table 2. Selected differentially expressed genes in kidney tissue of HFD mice versus 413 
chow mice 414 
 415 
Gene Symbol Gene Name log2 Ratio p Value 
Slc22a1 
solute carrier family 22 
member 1 (Oct1) 
0.07952 0.694 
Slc22a2 
solute carrier family 22 
member 2 (Oct2) 
0.2504 0.05479 
Slc22a3 
solute carrier family 22 
member 3 (Oct3) 
1.098 2.73E-05 
Slc47a1 
solute carrier family 47 
member 1 (Mate1) 
0.4208 0.0727 
Slc47a2 
solute carrier family 47 
member 2 (Mate2) 
-1.162 0.003459 













Table 3. Demographic information of patients with minimal change kidney disease 427 
 428 
groups BMI<24  (n=17) 28≤BMI<40 (n=18) 
Gender (male/female) 10/7 10/8 
Age (year) 50.80 ± 7.61 52.61 ± 3.33 
Plasma Cho (mM) 3.822 ± 0.176 4.514± 0.177* 
Plasma TG (mM) 0.865± 0.056 2.486± 0.501* 
BMI (Kg/m2) 23.42± 0.278 28.17± 0.421* 
 429 
Abbreviations: BMI, body mass index; TG, triglyceride; Cho, cholesterol. Values represent 430 
mean ± S.E.M., student’s t test, *p<0.05. 431 
 432 
 433 
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